# Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

> **NCT05101265** · PHASE1 · UNKNOWN · sponsor: **PharmaMar** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Hepatic Impairment

## Interventions

- **DRUG:** Lurbinectedin
- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT05101265
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-09
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101265, "Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05101265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*